Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine

Long-term use of olanzapine, an antipsychotic drug, induces hypertriglyceridemia, resulting in a higher risk of cardiovascular disease. However, the effects and underlying mechanisms of short-term use of olanzapine on circulating triglyceride levels remain poorly understood. Here, the role of apolipoprotein A5 (apoA5), a regulator of triglyceride metabolism, was investigated in olanzapine-induced hypertriglyceridemia. Our multi-center clinical study recruited 36 schizophrenia patients who received short-term (8 weeks) of olanzapine. Besides, female C57BL/6J mice were treated with olanzapine (3 mg/kg/day versus 6 mg/kg/day) for 6 weeks. We demonstrated that short-term use of olanzapine increased plasma triglyceride and decreased plasma apoA5 levels in the patients and mice, with a negative correlation between the two factors. However, no obesity was observed in the patients and mice. Interestingly, olanzapine increased hepatic apoA5 protein in the mice, without significant changes in hepatic Apoa5 mRNA. Consistently, in vitro studies indicated that olanzapine increased medium triglyceride levels and decreased medium apoA5 levels in a dose-dependent manner in human HepG2 cells and primary mouse hepatocytes. Whereas the olanzapine treatment increased hepatic apoA5 protein in vitro, without effects on hepatic APOA5 mRNA. Of note, olanzapine increased the co-localization between apoA5 protein and accumulated lipid droplets in hepatocytes, as opposed to at the hepatocellular plasma membrane, in mouse liver as demonstrated by fluorescence staining. Therefore, our study indicated that short-term use of olanzapine induced hypertriglyceridemia due to defects of sorting and secretion of hepatic apoA5.

[1]  Yang Yang,et al.  Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Y. Qian,et al.  ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition , 2021, Journal of lipid research.

[3]  C. Correll,et al.  Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics , 2020, Drugs.

[4]  Shelly C. Lu,et al.  Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. , 2020, Cell metabolism.

[5]  I. Romenskaia,et al.  High density lipoprotein promotes nascent apolipoprotein A-V secretion from mRNA transfected cells. , 2019, Biochemical and biophysical research communications.

[6]  Shuiping Zhao,et al.  Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. , 2016, Biochemical and biophysical research communications.

[7]  J. Ou,et al.  Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials , 2016, Molecular Psychiatry.

[8]  T. Forte,et al.  Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism. , 2015, Current drug targets.

[9]  D. Vancampfort,et al.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.

[10]  S. Baker,et al.  Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers , 2015, Pathology.

[11]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[12]  K. Wenner,et al.  Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. , 2014, Atherosclerosis.

[13]  Xinmin Yin,et al.  Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[14]  Shuiping Zhao,et al.  The role of apolipoprotein A5 in obesity and the metabolic syndrome , 2013, Biological reviews of the Cambridge Philosophical Society.

[15]  M. A. Lasunción,et al.  Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro[S] , 2013, Journal of Lipid Research.

[16]  Xuan Gao,et al.  Influence of apolipoprotein A-V on hepatocyte lipid droplet formation. , 2012, Biochemical and biophysical research communications.

[17]  T. Forte,et al.  Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement. , 2012, Biochimica et biophysica acta.

[18]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[19]  S. Leal,et al.  Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. , 2011, Atherosclerosis.

[20]  G. Olivecrona,et al.  Apolipoprotein A-V; a potent triglyceride reducer. , 2011, Atherosclerosis.

[21]  Paul G Shekelle,et al.  Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. , 2011, JAMA.

[22]  G. S. Shelness,et al.  Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion[S] , 2011, Journal of Lipid Research.

[23]  R. Stafford,et al.  Increasing off‐label use of antipsychotic medications in the United States, 1995–2008 , 2011, Pharmacoepidemiology and drug safety.

[24]  C. Correll,et al.  Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.

[25]  J. Baik,et al.  Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. , 2010, Biochemical and biophysical research communications.

[26]  E. Johansson,et al.  Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole , 2010, International Journal of Obesity.

[27]  R. Coccurello,et al.  30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice , 2009, Journal of clinical psychopharmacology.

[28]  Barbara Napolitano,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[29]  Shuiping Zhao,et al.  Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐α , 2009, British journal of pharmacology.

[30]  T. Forte,et al.  Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice Published, JLR Papers in Press, December 3, 2007. , 2008, Journal of Lipid Research.

[31]  Jing-ping Zhao,et al.  Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. , 2008, JAMA.

[32]  P. Talmud Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. , 2007, Atherosclerosis.

[33]  Yen-Hui Chen,et al.  Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. , 2007, Pharmacological research.

[34]  H. Ploegh A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum , 2007, Nature.

[35]  H. Yoshida,et al.  Prediction of genetic risk for metabolic syndrome. , 2007, Atherosclerosis.

[36]  Li‐jun Wu,et al.  Association of human serum apolipoprotein A5 with lipid profiles affected by gender. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[37]  D. Brasaemle,et al.  Isolation of Lipid Droplets from Cells by Density Gradient Centrifugation , 2005, Current protocols in cell biology.

[38]  K. V. van Dijk,et al.  Apolipoprotein AV: low concentration, high impact. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[39]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[40]  L. Pennacchio,et al.  Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[41]  L. Pennacchio,et al.  Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase* , 2005, Journal of Biological Chemistry.

[42]  A. Cantafora,et al.  Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[43]  K. V. van Dijk,et al.  ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.

[44]  L. Pennacchio,et al.  Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[45]  J. W. Gallagher,et al.  Structure and Interfacial Properties of Human Apolipoprotein A-V* , 2003, Journal of Biological Chemistry.

[46]  Len A Pennacchio,et al.  Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[47]  P. Reitsma,et al.  Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.

[48]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[49]  B. Trump,et al.  Mouse liver cell culture , 1981, In Vitro.

[50]  B. Trump,et al.  Mouse liver cell culture , 1981, In Vitro.

[51]  T. Grandin,et al.  AVMA Guidelines for the Euthanasia of Animals: 2013 Edition , 2013 .

[52]  D. Battle,et al.  Diagnostic and Statistical Manual of Mental Disorders (DSM). , 2013, CoDAS.

[53]  Robert G. Parton,et al.  Opinion: Lipid droplets: a unified view of a dynamic organelle , 2006, Nature Reviews Molecular Cell Biology.

[54]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.